| Title | CXCR4 is a good survival prognostic indicator in multiple myeloma patients |
| Authors | Bao, Li Lai, Yueyun Liu, Yanrong Qin, Yazhen Zhao, Xiaosu Lu, Xijing Jiang, Qian Lu, Jin Huang, Xiaojun |
| Affiliation | Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Beijing 100871, Peoples R China. |
| Keywords | Multiple myeloma SDF-1 alpha CXCR4 Survival Bone marrow cells STEM-CELL TRANSPLANTATION HIGH-DOSE CHEMOTHERAPY IN-SITU HYBRIDIZATION PLASMA-CELLS GENETIC ABNORMALITIES DISEASE PROGRESSION C-KIT EXPRESSION BORTEZOMIB PHASE-3 |
| Issue Date | 2013 |
| Publisher | leukemia research |
| Citation | LEUKEMIA RESEARCH.2013,37,(9),1083-1088. |
| Abstract | SDF1 alpha and its receptor CXCR4 are involved in multiple myeloma (MM) by attracting and activating plasma cells in the bone marrow. CXCR4 expression in MM cells is inversely correlated with disease activity. The aim of this study was to evaluate CXCR4 as a prognostic tool in MM, as well as other markers of disease, such as chromosomal aberrancies. Purpose was to investigate the expression levels of SDF-1 alpha before and after bortezomib and thalidomide treatment. From February 2006 to April 2012, CXCR4 expression was prospectively assessed in bone marrow samples from a large population of patients( n = 227) using flow cytometry. Clinical characteristics were collected and chromosomal aberrancies were assessed in 144 patients. SDF-1 alpha levels were determined using ELISA in peripheral blood samples from 40 patients before and after chemotherapy. Our results show that CXCR4 was present in 43.2% (98/227) of newly diagnosed MM patients and that CXCR4 expression was significantly correlated with CD117( P < 0.05). CXCR4-positive MM patients had a significantly longer estimated survival time than CXCR4-negative patients (median of 48 vs. 42 months, P < 0.05). Multivariate survival analyses identified that the +1q21/CXCR4- phenotype is an independent survival predictor, along with the International Staging System (ISS) stage. No significant difference was observed in expression levels of SDF-1 alpha before and after bortezomib/thalidomide treatment. In conclusion, +1q21/CXCR4- could be an independent survival prognosis predictor in MM patients. Expression levels of SDF-1 alpha before and after bortezomib/thalidomidetreatment are not different, although they are higher than in controls. (C) 2013 Published by Elsevier Ltd. |
| URI | http://hdl.handle.net/20.500.11897/159293 |
| ISSN | 0145-2126 |
| DOI | 10.1016/j.leukres.2013.06.002 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 人民医院 |
